Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Fate Therapeutics
(NQ:
FATE
)
23.79
+1.15 (+5.08%)
Streaming Delayed Price
Updated: 12:41 PM EDT, May 17, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
413,733
Open
23.23
Bid (Size)
23.80 (1)
Ask (Size)
23.87 (1)
Prev. Close
22.64
Today's Range
22.88 - 24.01
52wk Range
20.49 - 97.06
Shares Outstanding
96,629,085
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Recap: Fate Therapeutics Q1 Earnings
May 04, 2022
Fate Therapeutics (NASDAQ:FATE) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Performance
YTD
-60.53%
-60.53%
1 Month
-32.95%
-32.95%
3 Month
-34.62%
-34.62%
6 Month
-55.72%
-55.72%
1 Year
-68.84%
-68.84%
More News
Read More
What 4 Analyst Ratings Have To Say About Fate Therapeutics
March 04, 2022
Via
Benzinga
Fate Therapeutics: Q4 Earnings Insights
February 28, 2022
Via
Benzinga
Earnings Scheduled For February 28, 2022
February 28, 2022
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Via
Benzinga
Fate Therapeutics's Earnings: A Preview
February 25, 2022
Via
Benzinga
Earnings Outlook For Fate Therapeutics
February 25, 2022
Via
Benzinga
2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch
February 08, 2022
Via
Benzinga
Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years?
January 14, 2022
Via
Benzinga
Here's How Much $100 Invested In Fate Therapeutics 5 Years Ago Would Be Worth Today
January 05, 2022
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
December 15, 2021
Via
Benzinga
The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks
December 14, 2021
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021
December 15, 2021
Via
Benzinga
Fate Therapeutics Showcases Interim Data From FT596 Cell Program In Lymphoma
December 14, 2021
Via
Benzinga
Hedge Funds Are Selling Vontier Corporation
December 11, 2021
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021
December 07, 2021
Via
Benzinga
Cathie Wood Likes Fate Therapeutics, Should You?
December 01, 2021
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021
November 09, 2021
Via
Benzinga
Fate Therapeutics, inc (FATE) Q3 2021 Earnings Call Transcript
November 05, 2021
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
Via
Benzinga
Exposures
COVID-19
3 Biotech Stocks to Watch Now
October 12, 2021
Via
Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Via
Benzinga
Recent Poor Results Have Made This Promising Cathie Wood Pick a Bargain
September 14, 2021
Via
The Motley Fool
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2021
August 26, 2021
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.